Breaking News Instant updates and real-time market news.

IRWD

Ironwood

$16.01

-0.06 (-0.37%)

, AGN

Allergan

$193.99

2.66 (1.39%)

07:01
12/22/16
12/22
07:01
12/22/16
07:01

Ironwood says CR2 numerically improved abdominal pain in IBS trial

IRWD

Ironwood

$16.01

-0.06 (-0.37%)

AGN

Allergan

$193.99

2.66 (1.39%)

IRWD Ironwood
$16.01

-0.06 (-0.37%)

04/26/16
JPMS
04/26/16
NO CHANGE
JPMS
Ironwood Linzess safety concerns overblown, says JPMorgan
04/26/16
COWN
04/26/16
NO CHANGE
COWN
Outperform
Ironwood short report does not discuss any new information, says Cowen
Cowen analyst Boris Peaker,commented on the short report on Ironwood (IRWD) issued by Phase Five Research and said it doesn't appear to discuss any new data. Peaker said the analysis ignores the co-morbidities of patients that are on Linzess, which has been in 2M patients, many with significant other illnesses and on multiple other background therapies. Additionally, the report overlooked the acquisition of Zurampic today from AstraZeneca (AZN) that was favorably structured with a $100M upfront payment to Ironwood, the analyst said. Peaker said feedback on Linzess from consultants at Cowen's Healthcare Conference was positive and reiterates his Outperform rating.
04/27/16
UBSW
04/27/16
NO CHANGE
Target $8
UBSW
Sell
Ironwood had no new safety concerns with Linzess, says UBS
UBS said the FDA had no new safety concerns and there were no regulatory actions required for Ironwood's Linzess drug. The firm expects the noise from yesterday's short report, which suggested the FDA had issues with Linzess, to subside as the safety concerns pointed to were not justified. UBS acknowledges they have not given much credit for the company's pipeline, but they prefer to stay on the sidelines and take a "wait and see" attitude. UBS maintained its Sell rating and $8 price target on Ironwood shares.
12/13/16
EVER
12/13/16
NO CHANGE
Target $296
EVER
Buy
Evercore says Linzess trial an 'under the radar' potential catalyst for Allergan
Evercore ISI analyst Umer Raffat said the readout of the Phase 2b trial of colonic-release Linzess, which is due before year end according to Ironwood (IRWD), is a "wayyy under the radar" potential catalyst for Allergan (AGN), which he notes is partnered on the drug. Expectations are "basically" for the trial to fail completely, but if formulation 1 of colonic release delivers Linzess-like efficacy or has better pain relief than Linzess, it would extend the tail or possibly grow the franchise, he said. In a "blue sky scenario," formulation 2 of colonic release would show good abdominal pain relief, which would open up several new indications for the drug, added Raffat, who has a Buy rating and $296 price target on Allergan shares.
AGN Allergan
$193.99

2.66 (1.39%)

12/09/16
SBSH
12/09/16
NO CHANGE
SBSH
Buy
Citi sees favorable setup for Allergan heading into 2017
After hosting meetings with management, Citi analyst Liav Abraham sees a favorable setup for Allergan shares heading into 2017. The analyst highlights the lowered revenue expectations following the recent Q3 results, ongoing "strong" performance from key franchises as well as pipeline and M&A optionality. Abraham keeps a Buy rating on the shares.
12/15/16
GSCO
12/15/16
DOWNGRADE
GSCO
Buy
Allergan downgraded to Buy from Conviction Buy at Goldman
12/21/16
BERN
12/21/16
NO CHANGE
BERN
Allergan acquisition has positive aspects, says Bernstein
After Allergan agreed to buy LifeCell, analyst Aaron Gal says that LifeCell seems to "merge well" with Allergan's aesthetics business. The analyst thinks that the acquisition should have "a fair number of synergies," while "LifeCell is another long duration asset that is not protected solely via patent protection." The analyst believes that the cost of the deal is "reasonable." He keeps a $275 price target and an Outperform rating on Allergan.

TODAY'S FREE FLY STORIES

AVP

Avon Products

$1.94

0.04 (2.11%)

, COTY

Coty

$17.05

0.2 (1.19%)

06:36
11/20/17
11/20
06:36
11/20/17
06:36
Recommendations
Avon Products, Coty analyst commentary  »

Coty may consider…

AVP

Avon Products

$1.94

0.04 (2.11%)

COTY

Coty

$17.05

0.2 (1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

06:36
11/20/17
11/20
06:36
11/20/17
06:36
Downgrade
Ligand rating change  »

Ligand downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.47

-0.06 (-0.07%)

06:36
11/20/17
11/20
06:36
11/20/17
06:36
Technical Analysis
iShares iBoxx $ High Yield Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$120.46

0.15 (0.12%)

06:35
11/20/17
11/20
06:35
11/20/17
06:35
Technical Analysis
iShares iBoxx $ Investment Grade Corporate Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLT

iShares 20+ Year Treasury Bond Fund

$126.39

0.93 (0.74%)

06:35
11/20/17
11/20
06:35
11/20/17
06:35
Technical Analysis
iShares 20+ Year Treasury Bond Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$24.99

-0.16 (-0.64%)

, BA

Boeing

$262.26

-1.44 (-0.55%)

06:35
11/20/17
11/20
06:35
11/20/17
06:35
Periodicals
Airbus faces challenges over stalled A380 Emirates deal, Reuters reports »

Airbus (EADSY) is facing…

EADSY

Airbus

$24.99

-0.16 (-0.64%)

BA

Boeing

$262.26

-1.44 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATCEY

Altice

06:34
11/20/17
11/20
06:34
11/20/17
06:34
Hot Stocks
Altice: Majority investor Next does not hold any margin loan exposure to Altice »

Information service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

$16.31

0.19 (1.18%)

06:34
11/20/17
11/20
06:34
11/20/17
06:34
Technical Analysis
iShares Silver Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USLV

VelocityShares 3x Long Silver ETN

$12.56

0.45 (3.72%)

06:34
11/20/17
11/20
06:34
11/20/17
06:34
Technical Analysis
VelocityShares 3x Long Silver ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATCEY

Altice

06:34
11/20/17
11/20
06:34
11/20/17
06:34
Hot Stocks
Breaking Hot Stocks news story on Altice »

Altice says will not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYR

DJ US Real Estate Index Fund

$82.14

-0.38 (-0.46%)

06:33
11/20/17
11/20
06:33
11/20/17
06:33
Technical Analysis
DJ US Real Estate Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATCEY

Altice

, ATUS

Altice USA

$19.86

-0.38 (-1.88%)

06:33
11/20/17
11/20
06:33
11/20/17
06:33
Periodicals
Altice says not in preparation of cash raising by means of equity issuance »

Altice N.V. (ATCEY)…

ATCEY

Altice

ATUS

Altice USA

$19.86

-0.38 (-1.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATCEY

Altice

06:33
11/20/17
11/20
06:33
11/20/17
06:33
Hot Stocks
Breaking Hot Stocks news story on Altice »

Altice: Management has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBB

iShares Nasdaq Biotechnology Index

$311.21

0.4 (0.13%)

06:33
11/20/17
11/20
06:33
11/20/17
06:33
Technical Analysis
iShares Nasdaq Biotechnology Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RYAAY

Ryanair

$118.88

1.45 (1.23%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Initiation
Ryanair initiated  »

Ryanair initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LABD

Daily S&P Biotech Bear 3x Shares

$5.40

0.01 (0.19%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Technical Analysis
Daily S&P Biotech Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWH

MSCI Hong Kong Index

$25.43

-0.17 (-0.66%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Technical Analysis
MSCI Hong Kong Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVP

Avon Products

$1.94

0.04 (2.11%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Recommendations
Avon Products analyst commentary  »

Coty may consider…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWG

iShares MSCI Germany

$32.71

-0.16 (-0.49%)

06:32
11/20/17
11/20
06:32
11/20/17
06:32
Technical Analysis
iShares MSCI Germany: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IJR

iShares Core S&P Small Cap ETF

$74.63

0.32 (0.43%)

06:31
11/20/17
11/20
06:31
11/20/17
06:31
Technical Analysis
iShares Core S&P Small Cap ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEM

MSCI Emerging Markets Index

$46.82

0.23 (0.49%)

06:31
11/20/17
11/20
06:31
11/20/17
06:31
Technical Analysis
MSCI Emerging Markets Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$50.26

0.48 (0.96%)

06:30
11/20/17
11/20
06:30
11/20/17
06:30
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$24.34

-0.07 (-0.29%)

06:30
11/20/17
11/20
06:30
11/20/17
06:30
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UDN

PowerShares DB US Dollar Index Down

$22.13

0.07 (0.32%)

06:29
11/20/17
11/20
06:29
11/20/17
06:29
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Wal-Mart

$97.47

-2.15 (-2.16%)

06:28
11/20/17
11/20
06:28
11/20/17
06:28
Downgrade
Wal-Mart rating change  »

Wal-Mart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 20

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.